News

Started to develop a screening system for cancer disease with Lynch syndrome

  • 운영자
  • Date 2021.01.26
  • Hit 1,439
SeaSun Biomaterials begins developing a screening system for cancer disease with Lynch syndrome


 
SeaSun Biomaterials, a company specializing in genome analysis and bio-diagnosis, announced on the 29th that it was selected as the lead agency for the development of screening tests for high-risk patients with Lynch syndrome in the'Post Genome Multi-Ministry Genome Project' supported by the Ministry of Trade, Industry and Energy.

Named as 'Development of a screening test for high-risk groups for Lynch syndrome and risk prediction algorithm based on integrated genome information', a total government support of 1.2 billion won will be provided over the next two years and eight months. SeaSun Biomaterials and Korea University Guro Hospital participate in joint research. The Ministry of Commerce, Industry and Energy is devoting policy support to commercialize a cancer disease management system optimized for Koreans.

Lynch Syndrome is an autosomal dominant inherited disease. The risk of cancer by region throughout life is 22-75% of the colon, 30-60% of the endometrium, 9-12% of the ovaries, 1-13% of the stomach, 4 of the ureter. It is known to be ~5%, small intestine 1-4%, pancreas 3-4%, hepatobiliary 2-7%, and brain 1-3%.

This syndrome is separate from Familial Adenomatous Polyposis (FAP), which is a representative hereditary disease in the large intestine (colon and rectum), and DNA such as MLH1, MSH2, MSH6, and PMS2 play a role in finding and fixing errors that appear during DNA replication. Mutation correction (MMR) gene mutations have been studied to be the cause.

An official at SeaSun Biomaterials said, "We plan to classify risk groups and provide customized management guidelines for congenital and acquired factors such as family history, lifestyle, and genomic analysis information for the suspected group with high cancer incidence." .

The company uses a real-time polymerase chain reaction (PCR) method using blood to screen microsatellite instability (MSI) and a high-efficiency DNA methylation detection technology (Epi-) that does not require pretreatment with bisulfite. TOP technology). If SeaSun Biomaterials develops a patient screening and lifelong management system using these technologies, the Korea University Guro Hospital plans to conduct a large-scale clinical trial for patients with suspected Lynch syndrome, verify and optimize it.

"Through this project, we will develop a'cancer disease management system' that can systematically manage cancer prevention and post-treatment monitoring for patients with suspected Lynch syndrome through this project," said Han-woo Lee, head of the supervised research director, and head of SeaSun Biomaterials Research Institute. In addition, it is expected that early diagnosis and early treatment are possible even for families of high-risk patients, thereby reducing the incidence and mortality of cancer and significantly reducing medical costs.”

Lynch syndrome is known to have a cancer incidence of up to 40 times higher than that of normal people. Recently, it has been reported that changes in DNA methylation caused by environmental factors such as smoking, alcohol, fine dust, and stress further promote cancer.

Accordingly, the analysis of the genetic mutation caused by acquired factors, that is, the epigenetic genome, is being emphasized. In advanced countries such as the United States and the United Kingdom, early recognition of the risk of Lynch syndrome is trying to establish a'lynch syndrome prediction model'. In the United States, it is reported that 3.5 million new cases of Lynch syndrome occur each year.

관련전문:
http://www.fnnews.com/news/201905291311363492
http://www.viva100.com/main/view.php?key=20190529010009482
http://www.edaily.co.kr/news/read?newsId=03047126622493840&mediaCodeNo=257&OutLnkChk=Y
SNS Share 공유하기
Error Message : Query was empty